Fertility
Sensapex and IVF2.0 announce collaboration to enhance sperm injection for human IVF
Sensapex will integrate its ultra-precise micromanipulators and microscope automation capabilities with IVF2.0’s AI software

Sensapex (part of Acuvi AB), a leading developer of micromanipulators and automated workstations for cell manipulation, and IVF2.0, a pioneering provider of AI software for assisted reproductive technology (ART), have announced a strategic collaboration to further bring enhanced intracytoplasmic sperm injection (ICSI) solutions to the human IVF market.
Under the terms of the agreement, Sensapex will integrate its ultra-precise micromanipulators and microscope automation capabilities with IVF2.0’s innovative AI software that assists ICSI sperm selection.
By combining Sensapex’s cutting-edge hardware with IVF2.0’s data-driven software insights, the partners aim to develop the most advanced ICSI platform available.
“We are thrilled to partner with the outstanding team at IVF2.0 to merge our complementary areas of expertise in reproductive technology”, says Mikko Vähäsöyrinki, founder of Sensapex and VP of Acuvi Life Science Instrumentation business unit.
“This collaboration will allow us to deliver sophisticated new ICSI tools that improve consistency, precision and outcomes for IVF clinics and patients.”

Dr Andrew Drakeley, CEO of IVF2.0, says: “Sensapex is a perfect match for us as we enhance our AI software offerings.
“Their unique digitally integrated micromanipulation solutions will provide the specialised instrumentation to enhance our AI guidance smoothly and effectively in real-world IVF workflows.”
The companies expect the new integrated platform to be available for piloting by ART (Assisted Reproductive Technology) professionals within the next year.
About Sensapex
Sensapex provides cutting-edge robotic micromanipulators, microinjectors, and imaging systems for precision cell manipulation to labs and clinics worldwide. Learn more at www.sensapex.com.
About IVF2.0
IVF2.0 has the mission of improving IVF outcomes through Artificial Intelligence. Its innovative software platform uses AI and computer vision technology to enhance every step of the IVF process. Learn more at https://www.ivf20.ai/

Fertility
Gum disease may impair female fertility and egg quality – study
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Mental health
Housing, work and fertility stop Britons having the families they want – research
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Menopause5 days agoPerimenopause misinformation ‘putting women at risk’
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause3 weeks agoCBT shows promise for menopause insomnia and hot flashes
Mental health4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’













